Pharmigene Licenses IP to Mayo Clinic for Companion Dx for Stevens-Johnson Syndrome | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pharmigene today said it has licensed its intellectual property to the Mayo Clinic to develop tests to detect the presence of genetic alleles that may put patients who receive certain drugs at greater risk for developing Stevens-Johnson Syndrome and toxic epidermal necrolysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.